Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Viridian Therapeutics Inc (VRDN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: VRDN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 115.26% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.02B USD | Price to earnings Ratio - | 1Y Target Price 39.69 |
Price to earnings Ratio - | 1Y Target Price 39.69 | ||
Volume (30-day avg) 832697 | Beta 1.09 | 52 Weeks Range 11.40 - 27.20 | Updated Date 04/2/2025 |
52 Weeks Range 11.40 - 27.20 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -121488.89% |
Management Effectiveness
Return on Assets (TTM) -30.32% | Return on Equity (TTM) -48.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 515846972 | Price to Sales(TTM) 3388.91 |
Enterprise Value 515846972 | Price to Sales(TTM) 3388.91 | ||
Enterprise Value to Revenue 1708.1 | Enterprise Value to EBITDA -3.18 | Shares Outstanding 81485000 | Shares Floating 76929941 |
Shares Outstanding 81485000 | Shares Floating 76929941 | ||
Percent Insiders 0.12 | Percent Institutions 113.85 |
Analyst Ratings
Rating 4.47 | Target Price 40.44 | Buy 5 | Strong Buy 10 |
Buy 5 | Strong Buy 10 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Viridian Therapeutics Inc
Company Overview
History and Background
Viridian Therapeutics, Inc. is a biotechnology company founded in 2018, focused on developing therapies for patients with serious diseases but is best known for its Thyroid Eye Disease (TED) therapeutics. The company went public in 2020. It has since progressed multiple clinical programs targeting TED.
Core Business Areas
- Thyroid Eye Disease (TED) Therapeutics: Viridian's core business focuses on developing and commercializing antibody-based therapies for TED. These therapies aim to address the underlying causes of the disease and provide improved treatment options for patients.
Leadership and Structure
The company's leadership team consists of experienced biotechnology executives. The structure involves research and development, clinical operations, and commercialization divisions.
Top Products and Market Share
Key Offerings
- VRDN-001: VRDN-001 is Viridian's lead clinical candidate, an anti-IGF-1R antibody, used to treat TED. It is currently in clinical trials, specifically a Phase 3 trial. Competitors include Tepezza (teprotumumab) by Horizon Therapeutics (acquired by Amgen). Market share data is not currently available, as VRDN-001 is not yet approved for commercial use. Revenue is currently $0.
- VRDN-003: VRDN-003 is another anti-IGF-1R antibody with an extended half-life, under development for the treatment of TED. It is designed for less frequent subcutaneous administration. It is currently in clinical trials. Competitors are similar to VRDN-001, including Tepezza. Market share data and revenue is not yet available.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the market for rare and autoimmune diseases like Thyroid Eye Disease (TED), is experiencing substantial growth, driven by increasing disease awareness, diagnostic improvements, and the development of innovative therapies.
Positioning
Viridian Therapeutics is positioning itself as a key player in the TED treatment market by developing differentiated anti-IGF-1R antibodies with potentially improved efficacy, safety, and convenience compared to existing therapies.
Total Addressable Market (TAM)
The TED market is estimated to reach several billion dollars. Viridian aims to capture a significant share of this market with its pipeline of novel therapies. The TAM is estimated to be around $3 billion annually.
Upturn SWOT Analysis
Strengths
- Strong pipeline of anti-IGF-1R antibodies
- Potential for improved efficacy and safety compared to existing TED treatments
- Experienced management team
- Novel delivery mechanism
- Orphan drug designation potential
Weaknesses
- Reliance on clinical trial success
- Limited commercialization experience
- High cash burn rate
- Limited number of products
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory approval and market launch
- Advancements in manufacturing processes
Threats
- Clinical trial failures
- Competition from established players (e.g., Amgen/Horizon)
- Regulatory hurdles
- Patent challenges
- Adverse events in clinical trials
Competitors and Market Share
Key Competitors
- AMGN
Competitive Landscape
Viridian faces competition from established pharmaceutical companies with approved TED treatments. However, Viridian's pipeline of novel therapies and potential for improved efficacy and safety give it a competitive advantage. Their pipeline provides promise for a market share grab.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The historical growth is characterized by progression of its clinical programs and expansion of its pipeline.
Future Projections: Future growth is dependent on the successful completion of clinical trials, regulatory approval, and commercialization of its therapies.
Recent Initiatives: Recent initiatives include initiation of Phase 3 clinical trials for VRDN-001 and advancing VRDN-003 into clinical development. Viridian has also focused on strengthening its intellectual property portfolio.
Summary
Viridian Therapeutics is a development-stage biotechnology company focused on TED therapies, which is a very specialized space. Its strength lies in its pipeline of novel antibodies, but its weakness is its reliance on clinical trial success. It needs to successfully complete clinical trials and navigate regulatory hurdles to capitalize on its opportunities and mitigate the threats from established players and regulatory challenges. The company is positioned for growth in a market with a high unmet need, provided its clinical programs are successful.
Similar Companies
HALO
Halozyme Therapeutics Inc
HALO
Halozyme Therapeutics Inc
IMVT
Immunovant Inc
IMVT
Immunovant Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is approximate and may vary based on source and methodology. Clinical trial results are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Viridian Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2014-06-18 | CEO, President & Director Mr. Stephen F. Mahoney J.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 143 | |
Full time employees 143 | |||
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also offers VRDN-006 that is in Phase 1 clinical trial and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.